111, Inc. (YI) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
YI Revenue Growth
Revenue Breakdown (FY 2024)
YI's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
YI Revenue Analysis (2016–2024)
As of May 8, 2026, 111, Inc. (YI) generated trailing twelve-month (TTM) revenue of $14.18 billion, reflecting moderate decline in growth of -6.4% year-over-year. The most recent quarter (Q2 2025) recorded $3.21 billion in revenue, down 9.2% sequentially.
Looking at the longer-term picture, YI's 5-year compound annual growth rate (CAGR) stands at +29.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $14.95 billion in 2023.
Revenue diversification analysis shows YI's business is primarily driven by Product (50%), Drugs (47%), and Nutritional Supplements (2%).
When compared to Healthcare sector peers including HIMS (+59.0% YoY), TDOC (-1.5% YoY), and PINC (-16.2% YoY), YI has underperformed the peer group in terms of revenue growth. Compare YI vs HIMS →
YI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| YICurrent | $14.2B | -6.4% | +29.5% | 0.0% | |
 HIMS | $2.3B | +59.0% | +73.6% | 5.2% | |
 TDOC | $2.5B | -1.5% | +18.3% | -10.4% | |
 PINC | $1.0B | -16.2% | -4.9% | 0.1% | |
 CRON | $193M | +64.4% | +32.9% | -1.5% | |
 OPRX | $109M | +18.8% | +20.4% | 10.7% |
YI Historical Revenue Data (2016–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $14.40B | -3.7% | $829.2M | 5.8% | $2.1M | 0.0% |
| 2023 | $14.95B | +10.6% | $448.4M | 3.0% | $-350,097,000 | -2.3% |
| 2022 | $13.52B | +8.8% | $840.0M | 6.2% | $-371,001,000 | -2.7% |
| 2021 | $12.43B | +51.5% | $621.1M | 5.0% | $-642,140,000 | -5.2% |
| 2020 | $8.20B | +107.6% | $365.8M | 4.5% | $-473,311,000 | -5.8% |
| 2019 | $3.95B | +121.3% | $165.2M | 4.2% | $-493,513,000 | -12.5% |
| 2018 | $1.79B | +86.1% | $104.3M | 5.8% | $-400,375,000 | -22.4% |
| 2017 | $959.5M | +9.8% | $90.8M | 9.5% | $-254,022,000 | -26.5% |
| 2016 | $873.8M | - | $77.6M | 8.9% | $-364,280,000 | -41.7% |
See YI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs YI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare YI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonYI — Frequently Asked Questions
Quick answers to the most common questions about buying YI stock.
Is YI's revenue growth accelerating or slowing?
YI revenue declined -6.4% year-over-year, contrasting with the 5-year CAGR of +29.5%. TTM revenue fell to $14.2B. This reverses the prior growth trend.
What is YI's long-term revenue growth rate?
111, Inc.'s 5-year revenue CAGR of +29.5% reflects the variable expansion pattern. Current YoY growth of -6.4% is below this long-term average.
How is YI's revenue distributed by segment?
YI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.